DZ Bank reaffirmed their neutral rating on shares of Fresenius SE & Co KGaA (FRA:FRE) in a report issued on Friday.

A number of other analysts also recently weighed in on the stock. Independent Research set a €53.00 ($61.63) price target on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a report on Friday. Kepler Capital Markets set a €65.00 ($75.58) price target on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Friday. UBS Group set a €51.50 ($59.88) price target on shares of Fresenius SE & Co KGaA and gave the stock a sell rating in a report on Friday. Goldman Sachs Group set a €61.00 ($70.93) price target on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a report on Friday. Finally, Commerzbank set a €78.00 ($90.70) price target on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Friday. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of €68.69 ($79.88).

Shares of Fresenius SE & Co KGaA stock traded down €8.39 ($9.76) on Friday, reaching €38.99 ($45.34). 12,548,201 shares of the stock were exchanged. Fresenius SE & Co KGaA has a one year low of €60.16 ($69.95) and a one year high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Read More: Does the discount rate affect the economy?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.